Maturitas
Volume 55 , Pages S55-S63 , 1 November 2006

Vitex agnus castus: Successful treatment of moderate to severe premenstrual syndrome

References 

  1. Sternfeld B, Swindle R, Chawla A, Long S, Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol. 2002;99:1014–1024
  2. Singh BB, Berman BM, Simpson RL, Annchild A. Incidence of premenstrual symptome and remedy usage: a national probability sample study. Altern Ther Health Med. 1998;4:75–79
  3. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines of management. J Psychiatry Neurosci. 2000;45:459–468
  4. Wittchen HU, Becker E, Liebt R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder. Psychol Med. 2002;32:119–132
  5. American Psychiatric Association. Diagnostic and statistical manual of mental disoders, 4th ed. Washington, DC: Am. Psychiatric Ass. Press; 1994.
  6. Ho KY, Thorner MO. Therapeutic applications of bromcriptine in endocrine and neurological diseases. Drugs. 1988;36:67–82
  7. Pravidel®. Summary of product characteristics (Fachinformation), Novartis Pharma GmbH, Germany, status: February 2004.
  8. The Register of medicines of Russia (Encyclopaedia of medicines), issue 9, 2002;170–1.
  9. KiIicdag EB, Tarim E, Bagis T, et al. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Int J Gynaecol Obstet. 2004;85:292–293
  10. Wuttke W, Gorkow C, Jarry H. Dopaminergic compounds in Vitex agnus castus. In:  Loew RN,  Darmstadt D editor. Phytopharmaka in Foschung und klinischer Anwendung. Steinkopff Verlag; 1995;p. 81–91
  11. Christoffel V, Spengler B, Abel G, Jarry H, Wuttke W. Diterpenes from BNO 1095 (Vittex agnus castus) inhibit prolactin secretion. In: Proceedings of the 6th annual symposium on complementary health care. Exeter, UK. 1999;
  12. Jarry H, Christoffel V, Spengler B, Popp MA, Wuttke W. Diterpens isolated from Vitex agnus castus BNO 1095 inhibit prolactin secretion via specific interaction with dopamine D2 receptors in the pituitary, Jahrestagung der Ges. Für Phytotherapie, Münster; 1999.
  13. Merz PG, Gorkow C, Schrödter A, et al. The effects of a special Agnus Castus-extract (BP1095E1) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes. 1996;104(6):447–453
  14. Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol. 1994;102(6):448–454
  15. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste-tree (Vitex agnus castus)—pharmacology and clinical indications. Phytomedicine. 2003;10(4):348–357
  16. Brugisser R, Burkard W, Simmen U, Schaffner W. Untersuchungen an opioid-rezeptoren mit Vitex agnus castus L.. Phytotherapie. 1999;20(3):154–158
  17. Hoberg E. Phytochemical and analytical investigations of Vitex agnus castus L. (dissertation). Zürich, Switzerland: Swiss Federal Institute of Technology Zürich; 1999;Available from: Diss: ETH 13285
  18. Lauritzen Ch , Reuter HD, Repges R, Böhnert KJ, Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double-blind study vs. pyridoxine. Phytomedicine. 1997;4:183–189
  19. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322:134–137
  20. Halaska M, Beles P, Gorkow C, Sieder C. Treatment of ciclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast. 1999;8(4):175–181
  21. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol Clin Exp. 2003;18:191–195
  22. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome: the development or research diagnostic criteria and rating scale. Acta Psychiat Scand. 1980;62:177–190
  23. European Union, Eudralex, Vol. 9. Pharmacovigilance-Medicinal Products for Human use and Veterinary Medicinal Products, specifically therein Chapter 1.5; June/July 2004
  24. Agnucaston, Summary of product characteristics (Fachinformation), Bionorica AG, Germany, status of information; February 2004

PII: S0378-5122(06)00239-8

doi: 10.1016/j.maturitas.2006.06.017

Maturitas
Volume 55 , Pages S55-S63 , 1 November 2006

Article Tools

* Image Usage & Resolution